{
    "relation": [
        [
            "",
            "Early Pramipexole",
            "Delayed Pramipexole"
        ],
        [
            "Description",
            "1.5 milligrams/day pramipexole (for up to 15 months)",
            "Placebo (for first 6 to 9 months) + 1.5 milligrams/day pramipexole (for following 6 months)"
        ]
    ],
    "pageTitle": "Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00321854?sect=Xk015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987402.78/warc/CC-MAIN-20150728002307-00181-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 848763478,
    "recordOffset": 848747084,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: pramipexole Intervention: Parkinson Disease Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: December 18, 2009 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Early Pramipexole \u00a0 \u00a0 Delayed Pramipexole \u00a0 STARTED \u00a0 \u00a0 261 \u00a0 \u00a0 274 \u00a0 COMPLETED \u00a0 \u00a0 198 \u00a0 \u00a0 192 \u00a0 NOT COMPLETED \u00a0 \u00a0 63 \u00a0 \u00a0 82 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 41 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 43 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 14 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 6 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}